BackgroundAn unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R2 versus R2 in participants with relapsed or refractory follicular lymphoma after at least

Butler J, McMullan CJ, Anstrom KJ, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2025; 406: 1341–50—In figure 1 of this Article, the intention-to-treat population for the placebo group should have read “3052” patients. In the Geographical region section of figure 3, alignment of

BackgroundFollicular lymphoma is characterised by episodes of remission and relapse, with patients requiring multiple lines of therapy. Lenalidomide plus rituximab is a commonly used immunotherapy combination in patients with relapsed or refractory follicular lymphoma. We aimed to assess the efficacy and safety of adding tafasitamab, a CD19-targeted Fc-enhanced monoclonal antibody, to lenalidomide

No Abstract

BackgroundIn high-risk pregnancies, there is no reliable intervention to reduce term pre-eclampsia. We aimed to investigate the effect of screening for pre-eclampsia risk at 36 weeks' gestation and offering risk-stratified, planned, early-term birth.MethodsPREVENT-PE was an open-label, adaptive (planned, for sample size), randomised controlled trial, done at two maternity hospitals in the UK. We included

No Abstract

No Abstract

No Abstract

Section snippetsCaseDaniel, a 45-year-old asylum seeker from Ghana, presented with severe abdominal pain to a medical clinic in Tijuana, Mexico, which provides free primary care services for migrants requesting asylum in the USA. Daniel tells Dr V, an emergency medicine physician from Los Angeles, CA, USA, who volunteers at the clinic, that he experienced persecution for becoming romantically involved

No Abstract

Download: Download high-res image (250KB)Download: Download full-size image

No Abstract

No Abstract

No Abstract

No Abstract

Zannad F, O’Connor CM, Butler J, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet 2025; 406: 1351–62—In this Article, Prof Giuseppe M C Rosano's affiliations should have read San Raffaele Open University of Rome, Rome, Italy, and IRCCS San Raffaele Roma, Rome, Italy

Gevaert P, Desrosiers M, Cornet M, et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet 2025; 405: 911–26—In this Article, in the Results section, sentence 2 of paragraph 8 should have read, “One participant (who received depemokimab)”; in Appendix 1, in the Sensitivity

No Abstract

No Abstract

No Abstract

No Abstract

Section snippetsResponseThe Fijian Government has responded with a focused plan and strong political leadership. Previously, the annual HIV budget was FJD 200 000 (£67 000). This year, it has committed domestic funding of FJD 10 million (£3 million), which has enabled the establishment of a new dedicated Sexual Reproductive Health and HIV Unit within the MHMS, led by Jason Mitchell, a Fiji-born doctor

Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in Europe and North America and approximately 1% in Asia and South America. Accurate diagnosis relies on the presence of typical signs and symptoms, elevated natriuretic peptide concentrations, and evidence of cardiac structural or functional abnormalities using cardiac imaging techniques

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Download: Download high-res image (244KB)Download: Download full-size image

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Guerrero ME, Daniels DV, Makkar RR, et al. Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial. Lancet 2025; 406: 2541–50—In figure 2A of this Article, the p value should have read “p<0·0001”. In figure 3, a missing legend has been added for panel B and the figure

Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. Although it can present with an acute coronary syndrome, it is often characterised by long periods of stability, known as chronic coronary artery disease. This Review presents a comprehensive overview of the diagnosis of the disease, with a focus on cardiac imaging. We discuss various cardiac imaging modalities

No Abstract

Globally, the prevalence of chronic kidney disease is estimated to be approximately 850 million cases, with approximately 4 million individuals needing kidney replacement therapy for kidney failure. By 2050, chronic kidney disease is projected to become the fifth leading underlying cause of death worldwide. Despite its numerous causes, chronic kidney disease can be screened for, diagnosed, and staged

Rocatinlimab is a T cell rebalancing therapy that inhibits and reduces the number of pathogenic T cells by targeting the OX40 receptor expressed on the surface of activated T cells. Two global phase 3 studies were performed to assess the efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in adults.